EGFR and non-small cell lung carcinoma: The covalent binding of EGFR inhibits both the phosphorylation of EGFR kinase and the phosphorylation of downstream signaling substrates AKT and ERK, selectively and irreversibly targeting EGFR-sensitive mutations and T790M resistance mutations in patients with NSCLC.